A new treatment against epithelial transitions
A new treatment against epithelial transitions can finally solve a problem such as an invasion of cancer cells during radiotherapy and metastasis.
Metastasis is when cells are altered to proliferate rapidly and this uncontrolled proliferation by mitosis produces a primary tumor.
In fact the cells which constitute the tumor eventually undergo metaplasia, followed by dysplasia,anaplasia and ending in a malignant phenotype.
This malignancy allows invasions into the circulation, followed by invasion to a second site for tumorigenesis.
Here we created a new treatment against epithelial transitions, an orally available TGF-β type I receptor inhibitor.
In fact this new type of treatment was investigated in the 4T1-Luc allografted BALB/c syngeneic mouse model and in 4T1-Luc and MDA-MB-231 cells.
The therapeutic potential of vactosertib in breast cancer was investigated using fluorescence immunohistochemistry, a real-time quantitative reverse transcription-polymerase chain reaction.
Radiation induced TGF-β signaling, EMT marker , CSC properties , reactive oxygen species markers , and motility of breast cancer cells in vitro and in vivo.
Vactosertib attenuated the induced radiation and CSC properties by inhibiting ROS stress in breast cancer.
Moreover, vactosertib combined with radiation showed a significant anti-metastatic effect with suppression of breast to lung metastasis in vivo.
These results indicate that inhibition with vactosertib would be an attractive strategy for the prevention of cancer metastasis.